October 2025 in “Aquaculture” Coconut oil boosts testosterone but doesn't fully trigger reproductive maturity in pufferfish.
March 2026 in “Preprints.org” Platelet-rich plasma, microneedling with minoxidil, and topical finasteride are promising treatments for hair loss.
May 2025 in “Frontiers in Pharmacology” New treatments are needed for non-scarring alopecia due to current limitations.
17 citations
,
November 2021 in “Journal of Cosmetic Dermatology” Combination therapies for androgenetic alopecia work best but can have significant side effects and costs.
1 citations
,
October 2022 in “Evidence-based Complementary and Alternative Medicine” Traditional Chinese Medicine may help treat hair loss but needs more research.
September 2023 in “Medicina-lithuania” The study suggests that analyzing DNA can help treat hair loss, but more research is needed.
6 citations
,
January 2024 in “Cancers” Antiandrogens don't help with COVID-19 and aren't recommended.
1 citations
,
October 2025 in “Journal of Microbiology and Biotechnology” Natural extracts may promote hair growth with fewer side effects than conventional treatments.
13 citations
,
June 2024 in “Frontiers in Genetics” About 50% of 46, XY DSD cases lack a genetic diagnosis, but advanced sequencing methods improve detection.
Dr. Min's method for eyebrow and eyelash transplantation is effective, with most hairs regrowing, and proper recovery is crucial for success.
4 citations
,
April 2001 in “Experimental Dermatology” Using single dermal papillae is unreliable for analyzing androgen metabolism in hair follicles.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Androgenetic alopecia (AGA) is a common genetic condition affecting the scalp, caused by the conversion of testosterone to Dihydrotestosterone (DHT) by the enzyme 5-Alpha Reductase, leading to hair follicle shrinkage. Current FDA-approved treatments, finasteride and minoxidil, have limitations, prompting research into nanocarrier-based drug delivery systems like liposomes, solid lipid nanoparticles, and transferosomes. These systems offer improved drug stability, targeted delivery, and sustained release while minimizing systemic exposure. Innovations such as antioxidant formulations and spironolactone-loaded nanoparticles aim to reduce oxidative stress and block androgen receptors. Although preclinical results are promising, challenges remain in clinical translation, including the need for reliable trials, funding, and regulatory approval. The review highlights the importance of clinical validation and scalable production to harness nanotechnology's potential for AGA treatment.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Androgenetic alopecia (AGA) is a common genetic condition affecting the scalp, caused by the conversion of testosterone to Dihydrotestosterone (DHT) by the enzyme 5-Alpha Reductase, leading to hair follicle shrinkage. Current FDA-approved treatments, finasteride and minoxidil, have limitations, prompting research into nanocarrier-based drug delivery systems like liposomes, solid lipid nanoparticles, and transferosomes. These systems offer improved drug stability, targeted delivery, and sustained release while minimizing systemic exposure. Innovations such as antioxidant formulations and spironolactone-loaded nanoparticles aim to reduce oxidative stress and block androgen receptors. Despite promising preclinical outcomes, challenges remain in clinical translation, including the need for reliable trials, funding, and regulatory approval. The review highlights the importance of clinical validation and scalable production to harness nanotechnology's potential for AGA treatment.
6 citations
,
December 2016 in “Journal of Dermatology” Dutasteride effectively and safely treats male hair loss for over a year.
32 citations
,
August 1999 in “Journal of Investigative Dermatology” Early onset hair loss linked to genetics and androgen levels.
2 citations
,
January 2015 in “Journal of cosmetology & trichology” Need better hair loss treatments beyond minoxidil, finasteride, and transplants.
The document concludes that current hair loss treatments have limitations and suggests researching new treatments targeting different factors of hair loss.
Intradermotherapy with minoxidil is as effective as topical application for treating hair loss.
17 citations
,
January 2023 in “Nanoscale Advances” The microneedle arrays effectively promote wound healing and have potential for clinical use.
12 citations
,
October 2004 in “Experimental Gerontology” Changes in testosterone and estrogen receptor genes can affect how men age, influencing body fat, hair patterns, and possibly leading to skin disorders.
September 2025 in “Pharmaceutics” Quercetin nanocrystal gel shows promise for hair regrowth in androgenetic alopecia.
August 2024 in “Journal of Cosmetic Dermatology” CGF injections may safely and effectively promote hair growth in androgenetic alopecia patients.
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
4 citations
,
May 2019 in “The World Journal of Men's Health” Taking 5 alpha reductase inhibitor medication slightly increases the risk of depression, especially as you get older.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other compounds may help treat hair loss by inhibiting 5-alpha reductase.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules from plants may help treat hair loss.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules from plants may help treat hair loss.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules may help treat hair loss by inhibiting 5-alpha reductase.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
March 2016 in “European Urology Supplements” Methylation in specific gene region causes finasteride resistance in some BPH patients.